UnknownPhase 2

Reduced Dose Radiotherapy Following High Dose Chemotherapy in Intracranial Non-germinomatous Germ Cell Tumor

South Korea25 participantsStarted 2014-04

Plain-language summary

The purpose of this study is to evaluate the outcome of intracranial non-germinomatous germ cell tumor (NGGCT) treated with reduced radiotherapy following high dose chemotherapy and autologous stem cell transplantation (HDCT/auto-SCT).

Who can participate

Age range3 Years – 30 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Patients with pathologically proven intracranial non-germinomatous germ cell tumor or * Patients who have brain mass which are suspected as intracranial germ cell tumor and elevated serum or cerebrospinal fluid alpha-feto protein. Exclusion Criteria: * Patients with organ dysfunction (ejection fraction \<40%, creatinine \> 3 x upper limit of normal (ULN), aspartate aminotransferase/alanine aminotransaminase \> 5 x ULN). * Pregnant or nursing women

What they're measuring

Rate of event free survival

Timeframe: Up to 3 years

Trial details

NCT IDNCT02784054

SponsorSamsung Medical Center

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2021-03

Contact for this trial

Ki Woong Sung, MD, PhD

82-2-3410-3529 kiwoong.sung@samsung.com

View on ClinicalTrials.gov More Intracranial Non-germinomatous Germ Cell Tumor trials